Moderna is a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The company develops mRNA medicines for infectious diseases, cancer, rare diseases, and autoimmune conditions, with the first commercial product (Spikevax COVID-19 vaccine) approved in 2020 and ongoing development of seasonal flu, RSV, and oncology programs.
FDA VRBPAC adcomm for mRNA-1010 seasonal flu vaccine
Phase 3 mRNA-4157 + Keytruda IMpowerLung3 readout in NSCLC
While Moderna preps an entry to the oncology market next year with a personalized cancer vaccine, COVID sales are holding steady with several other vaccine launches underway around the world.
Two more Ebola vaccines are set to be added to a trial in the Democratic Republic of the Congo (DRC), currently battling its largest-ever outbreak.
Moderna faced pointed questions from a panel of U.S. judges as it defends its COVID-19 vaccine patents in a billion-dollar dispute.
Moderna's norovirus vaccine plans are in limbo after a Phase 3 miss, Fierce Biotech reports.
Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat
Moderna lost a US government-license defense in a patent case brought by Northwestern.
Have Moderna, Merck kicked off a 'personalized med revolution'? — latest biotechnology news.
Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’
Merck-Moderna cancer vax slows recurrence in ph. 3 trial
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
FDA approves Moderna's mRNA flu vaccine
US FDA approves first mRNA flu shot from Moderna, includes gallery
Moderna begins first human trial of Bundibugyo Ebola vaccine
Moderna's mRNA flu shot has won FDA approval, bouncing back after a refusal-to-file letter earlier this year and becoming the first approved mRNA flu vaccine.
Moderna is delaying the readout of its norovirus vaccine trial because the study has not yet accumulated enough infections to power the analysis.
Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain
Moderna beats quarterly revenue estimates ahead of key US flu vaccine decision
Moderna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departs — Endpoints News coverage of biopharma industry developments.
The FDA in February briefly refused to review Moderna’s flu vaccine, citing trial inadequacies, but reversed course a few days later. A verdict is expected by Aug. 5.
FDA advisory committee unanimously recommended Moderna's new mRNA influenza vaccine (mFlusiva) for adults 50 and over.
FDA vaccine advisors unanimously backed Moderna's flu vaccine, a departure from the prior FDA leadership's stance.
Moderna's mRNA flu vaccine backed by FDA advisers. (Reuters Biopharma.)
Weekly roundup: Moderna's mRNA flu shot heads to adcomm, IPO activity is picking up, and biopharma layoffs continue across multiple companies.
The FDA's Vaccines and Related Biological Products Advisory Committee meets June 18 to discuss Moderna's seasonal flu vaccine mRNA-1010 after the agency initially refused to accept the application in February.
Moderna has hired Ester Banque, a longtime Novartis commercial leader, as its new Chief Commercial Officer to prepare for upcoming product launches including the seasonal flu vaccine mRNA-1010.
Chief Executive Officer
Chief Financial Officer
Chief Commercial Officer (joined June 2026)